The 2016 revision of the World Health Organization classification of tumors of hematopoietic
and lymphoid tissues is characterized by a closer integration of morphology and molecular …

Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

Summary Background Erythropoiesis-stimulating agents (ESAs) are the standard-of-care
treatment for anaemia in most patients with lower-risk myelodysplastic syndromes but …

With a growing aged population, there is an imminent need to develop new therapeutic
strategies to ameliorate disorders of hematopoietic aging, including clonal hematopoiesis …

Importance Myelodysplastic neoplasms (MDS), formerly known as myelodysplastic
syndromes, are clonal hematopoietic malignancies that cause morphologic bone marrow …

The TGF-β signaling pathway governs key cellular processes under physiologic conditions
and is deregulated in many pathologies, including cancer. TGF-β is a multifunctional …

Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms
that are characterized by ineffective hematopoiesis, variable cytopenias, and a risk of …

PURPOSE Patients with lower-risk (LR) myelodysplastic syndromes (MDS) who are RBC
transfusion dependent and have experienced relapse after or are refractory to erythropoiesis …

People with human immunodeficiency virus (HIV) have higher rates of certain comorbidities,
particularly cardiovascular disease and cancer, than people without HIV,,,–. In view of …

Myelodysplastic Syndromes MDS are clonal hematopoietic disorders involving morphologic
defects and peripheral-blood cytopenias, with a risk of progression to acute myeloid …